For the quarter ending 2026-03-31, WGSWW made $102,254K in revenue. -$63,569K in net income. Net profit margin of -62.17%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Total revenue | 102,254 | 77,310* | 116,743 | |
| Cost of services | 34,043 | 32,718* | 32,216 | |
| Gross profit | 68,211 | 44,592* | 84,527 | |
| Research and development | 19,804 | 12,539* | 19,829 | |
| Selling and marketing | - | 17,875* | 23,510 | |
| General and administrative | - | 17,502* | 44,439 | |
| Selling, general and administrative | 74,591 | - | - | |
| Impairment loss | 31,287 | 0* | - | |
| Other operating expenses, net | - | 0* | - | |
| Loss from operations | -57,471 | -3,324* | -3,251 | |
| Change in fair value of financial liabilities | 2,540 | 8,999* | -3,401 | |
| Interest expense, net | -717 | -853* | -562 | |
| Loss on extinguishment of debt | -6,565 | - | - | |
| Other (expense) income, net | -206 | -3,795* | -174 | |
| Total non-operating expense, net | -4,948 | 4,351* | -4,137 | |
| Gain before income taxes | -62,419 | 1,027* | -7,388 | |
| Income tax expense | 897 | -857* | 247 | |
| Net gain | -63,316 | 1,884* | -7,635 | |
| Unrealized (gain) loss related to available for sale securities, net | -253 | -464* | 190 | |
| Comprehensive gain | -63,569 | 1,420 | -7,445 | |
| Basic EPS | -2.16 | 0.05 | -0.27 | |
| Diluted EPS | -2.16 | 0.05 | -0.27 | |
| Basic Average Shares | 29,335,126 | 28,485,738 | 28,797,730 | |
| Diluted Average Shares | 29,335,126 | 28,485,738 | 28,797,730 | |
GeneDx Holdings Corp. (WGSWW)
GeneDx Holdings Corp. (WGSWW)